drugset / Trial / NCT03588923
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With HCV Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple ascending doses of SH229 in patients with chronic hepatitis C Virus infection.
Timeline
- Start
- 2018-07-07
- Primary completion
- 2018-08-10
- Completion
- 2018-08-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SH229 | Unknown | 400 mg | Oral |
| Comparator | SH229 | Unknown | 600 mg | Oral |
| Comparator | SH229 | Unknown | 800 mg | Oral |